Zombie Biotech Bite Lilly’s Flab Fight Flops
This week’s ‘The Readout LOUD’ brings us the sad, slow death of a zombie biotech, proving you can’t just stitch dead companies back to life. Meanwhile, Lilly’s obesity drug results are as underwhelming as a flat soda—described simply as ‘disappointing obesity readout.’ If we were looking for a plot twist, we’d better sit down: pharma’s horror story continues with a whimper rather than a bang.
Share the Story
(1 of 3)When zombie biotechs stumble and Lilly’s obesity hopes deflate, it’s official: pharma’s more horror story than thriller right now.
Nothing like a biotech graveyard plus disappointment in obesity trials to remind us life and science both love an ironic twist.
If your biotech’s a zombie and your obesity study flops, congrats—you’re the pharmaceutical equivalent of a microwave dinner no one really wanted.
Source: Statnews | Published: 8/7/2025 | Author: Adam Feuerstein, Elaine Chen, and Allison DeAngelis
More Articles in Health
VP Vance Heads to Pakistan to Broker Peace, Backed by Kushner and Trump’s Threats
Augusta Airport Now Essentially a Billionaires' Landing Strip, Not a Regional Hub
FAA Turns to Gamers Because Real Air Traffic Controllers Keep Vanishing
Telehealth Startup Outsources Doctors to AI and Angolan Phone Lines
Widow Turns Frozen Sperm Time Capsule Into Baby After 10-Year Hiatus
OpenAI CEO Temporarily Downgrades from AI Overlord to Human POTS Patient
Woman Quits Job at 38 to Audit Diaper Changing as Full-Time Gig
Utah Lets Robot Shrink Prescribe Meds, Because What Could Go Wrong?
